Acute myocardial infarction following paclitaxel administration for ovarian carcinoma.
Evidence linking paclitaxel to cardiotoxicity arose from early Phase I trials in which continuous cardiac monitoring was performed because of the high incidence of major hypersensitivity reactions. A variety of cardiac manifestations have been reported, ranging from asymptomatic sinus bradycardia to fatal myocardial infarction. The following case report describes an acute myocardial infarction occurring shortly after paclitaxel therapy.
Laher
S
S
Clinical Oncology Centre, North Middlesex Hospital, London, UK.
Karp
S J
SJ
D000972:Antineoplastic Agents, Phytogenic / Q000009:adverse effects*; D005260:Female; D006801:Humans; D008875:Middle Aged; D009203:Myocardial Infarction / Q000139:chemically induced*; D010051:Ovarian Neoplasms / Q000188:drug therapy*; D017239:Paclitaxel / Q000009:adverse effects*
D000972:Antineoplastic Agents, Phytogenic; D017239:Paclitaxel